Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 29,500 shares of Edwards Lifesciences Corp stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $85.38, for a total value of $2,518,710.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares of the company’s stock, valued at approximately $22,527,513. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.42% during mid-day trading on Thursday, hitting $85.91. 425,502 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $87.03. The stock’s 50-day moving average is $82.7 and its 200-day moving average is $73.79. The company has a market cap of $9.063 billion and a price-to-earnings ratio of 30.77.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.07. The company had revenue of $522.40 million for the quarter, compared to the consensus estimate of $523.10 million. During the same quarter in the previous year, the company posted $0.72 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.17 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on EW shares. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences Corp in a research note on Thursday. They now have a $89.00 price target on the stock. Separately, analysts at JMP Securities upgraded shares of Edwards Lifesciences Corp from a “market perform” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $97.00 price target on the stock. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $87.00 to $90.00 in a research note on Thursday, May 22nd. They now have a “buy” rating on the stock. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $83.24.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.